Rankings
▼
Calendar
TNGX Q1 2020 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
Q1 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
Gross Profit
-$6M
-129.7% margin
Operating Income
-$8M
-171.2% margin
Net Income
-$8M
-168.0% margin
EPS (Diluted)
$-0.74
Cash Flow
Operating Cash Flow
-$12M
Free Cash Flow
-$12M
Stock-Based Comp.
$408,000
Balance Sheet
Total Assets
$0
Total Liabilities
$0
Stockholders' Equity
$8M
Cash & Equivalents
-$40M
← FY 2020
All Quarters
Q2 2020 →